None listed
Conditions
Brief summary
This research study will evaluate and update the efficiency of an old and new form of test to detect hCG in blood for an antidoping setting.
Interventions
Single dose of Recombinant human Chorionic Gonadotrophin (250 micrograms, r-hCG, Ovidrel, MerckSerono, Australia, ARTG 96037) and Urinary human chorionic gonadotrophin (5000 IU, u-hCG, Pregnyl, Merck/Schering Plough/Organon, Australia; ARTG 14518). Two phase cross over open and unblinded treatment. Subcutaneous injections are given by trained registered nurses in a hospital setting.
The drugs are given at 2 week intervals without a specific washout period but the drug effects lasts about a week
Single dose of Recombinant human Chorionic Gonadotrophin (250 micrograms, r-hCG, Ovidrel, MerckSerono, Australia, ARTG 96037) and Urinary human chorionic gonadotrophin (5000 IU, u-hCG, Pregnyl, Merck/Schering Plough/Organon, Australia; ARTG 14518). Two phase cross over open and unblinded treatment. Subcutaneous injections are given by trained registered nurses in a hospital setting. The drugs are given at 2 week intervals without a specific washout period but the drug effects lasts about a week (varies betwene individuals) and is not critical in this study. Just need samples from men exposed to both
Sponsors
Sydney Local Health District
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
Male
Age
18 Years to 56 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy males over the age of 18
Exclusion criteria
History of any chronic disease or condition requiring regular medical management History of male infertility or pituitary-testicular dysfunction History of androgen (anabolic steroid) use or abuse Allergic or other severe adverse reaction to hCG injections or their ingredients
Outcome results
None listed